Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B

[1]  P F Thall,et al.  Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. , 1999, Blood.

[2]  J. Miguel,et al.  Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia , 1998 .

[3]  M. Minden,et al.  Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. , 1998, Blood.

[4]  P. Fenaux,et al.  Retinoic Acid Syndrome , 1998, Drug safety.

[5]  P. Allen,et al.  Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. , 1997, Blood.

[6]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[7]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[8]  E. Pogliani,et al.  Thrombotic complications in acute promyelocytic leukemia during all-trans-retinoic acid therapy. , 1997, Acta haematologica.

[9]  Y-M Zhu,et al.  Down‐regulation of bcl‐2 in AML blasts by all‐trans retinoic acid and its relationship to CD34 antigen expression , 1996, British journal of haematology.

[10]  F. Mandelli,et al.  AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.

[11]  Zhen-yi Wang,et al.  [Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia]. , 1997, Zhonghua nei ke za zhi.

[12]  M. Minden,et al.  Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response to chemotherapy. , 1996, Leukemia.

[13]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[14]  E. Estey,et al.  Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. , 1996, Leukemia & lymphoma.

[15]  M. Minden,et al.  Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. , 1995, Leukemia.

[16]  G. Marit,et al.  Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. , 1995, Leukemia.

[17]  J. Bennett,et al.  A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). , 1995, Blood.

[18]  M. Tribalto,et al.  All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia. , 1995, Leukemia.

[19]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[20]  R. Bouabdallah,et al.  A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. , 1995, The New England journal of medicine.

[21]  G. Núñez,et al.  Regulation and function of Bcl-2 during differentiation-induced cell death in HL-60 promyelocytic cells. , 1995, The American journal of pathology.

[22]  N. Bown,et al.  De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Northern Region Haematology Group. , 1995, Leukemia.

[23]  M. Minden,et al.  Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia. , 1994, Leukemia.

[24]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[25]  N. Tsukada,et al.  Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. , 1994, Leukemia.

[26]  C. Bloomfield,et al.  Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. , 1994, Cancer genetics and cytogenetics.

[27]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[28]  M. Minden,et al.  Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. , 1993, Leukemia.

[29]  R. Mayer,et al.  The approach to the elderly patient with acute myeloid leukemia. , 1993, Hematology/oncology clinics of North America.

[30]  J. A. Liu Yin,et al.  ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT , 1993, British journal of haematology.

[31]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .

[32]  N. Gattermann,et al.  Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes , 1992, British journal of haematology.

[33]  R. Warrell,et al.  The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia , 1992, Annals of Internal Medicine.

[34]  H. Tilly,et al.  Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Löwenberg,et al.  On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Beuscart,et al.  Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases , 1989, British journal of haematology.

[37]  D. Golde,et al.  Treatment of acute myelogenous leukemia in the elderly. , 1989, Seminars in oncology.

[38]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[39]  M. Oken,et al.  Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia , 1988, British journal of haematology.

[40]  R. Gray,et al.  PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIAL , 1986, The Lancet.

[41]  J. Armitage,et al.  Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases , 1985, Cancer.

[42]  H. Brincker.  Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. , 1985, Cancer treatment reports.